Related Experiment Video

Updated: Jun 27, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Enalapril therapy and cardiac remodelling in sickle cell disease patients

Carmen S P Lima1, Osvaldo M Ueti, Adriana A Ueti

  • 1Haematology and Haemotherapy Centre, State University of Campinas, Campinas, São Paulo, Brazil. carmenl@fcm.unicamp.br

Acta Cardiologica
|November 19, 2008
PubMed

Insights

Angiotensin-converting enzyme inhibitors (ACEi) prevent cardiac remodeling in sickle cell disease (SCD) patients. Enalapril treatment halted increases in left ventricular mass and wall thickness observed in untreated SCD individuals.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Angiotensin-converting enzyme inhibitors (ACEi) are established treatments for cardiac dysfunction post-myocardial infarction.
  • Cardiac complications are a concern in sickle cell disease (SCD).

Purpose of the Study:

  • To investigate the cardiac effects of ACEi in patients with SCD.
  • To assess enalapril's impact on cardiac structure in SCD patients.

Main Methods:

  • Enalapril was administered to 9 SCD patients with microalbuminuria.
  • A control group of 9 SCD patients without microalbuminuria was followed for 36 months.
  • Echocardiograms were performed at baseline and after 36 months.

Main Results:

  • Untreated SCD patients showed increased left ventricular mass, wall thickness, and aortic root diameter.
  • Enalapril-treated SCD patients did not exhibit these cardiac remodeling changes.
  • No significant changes in left ventricular dimensions or ejection fraction were observed in either group.

Conclusions:

  • Enalapril appears to prevent cardiac remodeling in SCD patients.
  • Further large-scale trials are needed to confirm enalapril's efficacy in SCD.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...